Back to Screener

Yarrow Bioscience, Inc. - Common Stock (YARW)

NASDAQ
Data as of Mar 31, 2026 (TTM)

Investment Snapshot

  • Piotroski F-Score 3/9 — signs of financial weakness
  • Loss-making — negative ROE of -122.2%
  • Revenue growing at 14% annually

Yarrow Bioscience, Inc. - Common Stock (YARW) is a publicly traded company, listed on the NASDAQ . Key value metrics: Piotroski F-Score 3 out of 9 .

Value Score

Key Metrics

P/E Ratio
EPS
$-0.90
Div. Yield
PEG Ratio
P/S Ratio
EV/EBITDA
ROE
ROA
Gross Margin
Op. Margin
Net Margin
Debt/Equity
Current Ratio
Data sourced from SEC EDGAR and Polygon.io. Methodology.

Yarrow Bioscience, Inc. - Common Stock — Fundamental Analysis Summary

On financial health, YARW shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -122.2%.

StockPik's composite Value Score for YARW is 35/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.

YARW shows revenue growing at 14% year-over-year, with earnings growing at 34%.

How is the Value Score calculated?
Read our full methodology →
What is the Piotroski F-Score?
The 9-point financial health score explained, with worked examples →
Previous
YAAS
Next
YCBD